Investigació Aplicada en Malalties Respiratòries

Research team


Antoni Torres

Coordinator and Team Leader

Publications at PubMed

Professor in Medicine at the University of Barcelona (UB). He is considered a physician of reference both nationally and internationally in lung infections, including pneumonia, chronic obstructive pulmonary disease (COPD), bronchiectasis, immunocompromised patients, weaning, noninvasive ventilation (NIV), and acute respiratory distress syndrome (ARDS-ALI). He leads the research group on Management and prevention of infectious, interstitial and tumoral lung diseases of the August Pi i Sunyer Institute of Biomedical Research (IDIBAPS), from where he facilitates translational research studies.

He has taken part in many competitive research projects as principal researcher of the Health Care Research Fund (FIS). His research receives support from many public bodies, including the following: Carlos III Health Institute (ISCII), CibeRes, IDIBAPS, and the European Union. He is currently involved in more than 30 national, European and other international projects. He coordinates a CIBER group on respiratory diseases (CibeRes) and takes part in the European projects, GRACE, MOSAR (WP3, WP4) and Theraedge.

This team mainly investigates community-acquired and intrahospital respiratory infections. The aim is to answer questions arising from clinical observation of patients that are not in the literature and to obtain results that can be quickly applied to patient care in the diagnosis, treatment and prevention of nosocomial pneumonia. The team also studies community-acquired respiratory infections, from where they approach important questions such as the decision to admit to hospital, the decision to admit to the intensive care unit (ICU), microbial etiology, diagnostic tests and the most appropriate treatment to use. Other central study topics include noninvasive ventilation for the treatment of severe acute respiratory failure and weaning from artificial ventilation. At the same time, an animal model of severe pneumonia has been developed that allows trans-species research.

The research group is characterized by the utility of its results and their impact on clinical practice. For example, it has described measures for preventing nosocomial pneumonia and criteria for admitting patients to the ICU in community-acquired pneumonia, which have been adopted universally. The group’s studies on noninvasive ventilation have meant that this technique can be applied to patients with severe respiratory failure and extrapolate it to routine clinical practice. It is research aimed at improving clinical practice and quality of patient care.


  • International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the E

     Torres A, Niederman MS, Chastre J, Ewig S, Fernandez-Vandellos P, Hanberger H, Kollef M, Li Bassi G, Luna CM, Martin-Loeches I, Paiva JA, Read RC, Rigau D, Timsit JF, Welte T, Wunderink R.  

    Eur Respir J. 2017 Sep 10;50(3). pii: 1700582. doi: 10.1183/13993003.00582-2017. Print 2017 Sep.

    More information


He is considered a physician of reference both nationally and internationally in lung infections and leads this IDIBAPS team from where he carries out translational research studies

Involved in the following lines